FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385698081> ?p ?o ?g. }

• W4385698081 endingPage "e481931f" @default.
• W4385698081 startingPage "e481931f" @default.
• W4385698081 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Diffuse large B-cell lymphoma (DLBCL) is a lymphoproliferative disease with a highly heterogeneous clinical course and prognosis. Advanced-stage DLBCL may spread to extranodal sites, especially to the bone marrow, pleura, peritoneum, liver, and central nervous system (CNS). Although the risk of CNS relapse in the course of DLBCL was defined as 2-5%, this rate has decreased with the onset of the rituximab-based immunochemotherapy era. High initial absolute lymphocyte count (ALC) contributed positively to the course of the lymphomas. It has been shown that a high ALC at the time of diagnosis was associated with longer time to progression (TTP) and better treatment response. Therefore, high ALC at the time of diagnosis may be protective in terms of CNS relapse, while low ALC may guide in terms of CNS relapse and may be included in prognostic indexes. Aims: In this study, it was aimed to develop a new risk model adding the ALC at the time of diagnosis in order to predict CNS relapse and to develop a new risk model superior compared to the CNS-IPI. Methods: Patients diagnosed with DLBCL and followed up in Istanbul Training and Research Hospital, Hematology Clinic between January 2005, and July 2021 were included in the study. In addition to the demographic data such as age and gender, the stage at the time of diagnosis, presence of extranodal involvement, performance status, presence of renal/adrenal gland involvement, laboratory data (Leukocyte, neutrophil, lymphocyte, hemoglobin, platelet, LDH), presence of bone marrow involvement and survival data were recorded. The patients’ CNS-IPI scores were calculated, and the efficacy was evaluated in our own DLBCL population. Statistical analyses were renewed for the effectiveness of the “CNS-Samatya” risk model obtained by adding the ALC cut-off determined in our study. Results: In the ROC analysis in terms of estimating CNS relapse, the area under the curve (AUC) for the ALC cut-off of 1630/mm3 was 0.644 (95% CI: 0.534-0.755, p=0.021). The sensitivity was 78% and the specificity was 56%. CNS relapse was 4.591 times higher in those with an ALC of 1630/mm3 and lower than in those with an ALC above 1630/mm3. There was a significant relationship between the determined ALC cut-off and the stage at the time of diagnosis (p<0.05). While 50.7% of those with extranodal involvement had an ALC of 1630/mm3 and below, 60.3% of those without involvement had an ALC of above 1630/mm3. Extranodal involvement was found to be significantly higher on the determined ALC cut-off (p=0.039). There was also a significant correlation between the determined ALC cut-off and mortality (p=0.01). During the follow-up period, 59.9% of the survivors had an ALC above 1630/mm3 at the time of diagnosis, while 57.6% of patients with a mortal course had an ALC of 1630/mm3 and below. The effects of the CNS-Samatya and the CNS-IPI risk models on both CNS relapse and mortality were evaluated with separate statistical analyzes in our patient series. In the ROC analysis in terms of estimating CNS relapse, the AUC for the CNS-IPI for 1.5 cut-off value was 0.691 (95% CI: 0.061-0.771, p=0.002); the sensitivity was 100%, the specificity was 37%. For the CNS-Samatya for 2.5 cut-off value, the AUC was 0.756 (95% CI: 0.684-0.827, p<0.001), the sensitivity was 91%, and the specificity was 57%. In the statistical analysis in terms of estimating mortality, the AUC for the CNS-IPI for 2.5 cut-off value was 0.611 (95% CI: 0.55-0.673, p<0.001), the sensitivity was 36%, and the specificity was 79%. For the CNS-Samatya for 2.5 cut-off value, the AUC was 0.644 (95% CI: 0.584-0.704, p<0.001), the sensitivity was 62%, and the specificity was 62%. Summary/Conclusion: In the analysis made in terms of estimating mortality, the CNS-Samatya risk model was superior compared to CNS-IPI. Our results showed the effectiveness of the ALC at the time of diagnosis and the CNS-Samatya risk model created by adding initial ALC, and will shed light on future studies. Figure 1. ROC curves in terms of estimating central nervous system (CNS) relapse: Comparison of CNS-IPI and CNS-SamatyaKeywords: CNS lymphoma, Relapse, Prognosis, Diffuse large B cell lymphoma" @default.
• W4385698081 created "2023-08-10" @default.
• W4385698081 creator A5012295709 @default.
• W4385698081 creator A5054467773 @default.
• W4385698081 creator A5090573083 @default.
• W4385698081 date "2023-08-01" @default.
• W4385698081 modified "2023-09-27" @default.
• W4385698081 title "PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL" @default.
• W4385698081 doi "https://doi.org/10.1097/01.hs9.0000976056.48193.1f" @default.
• W4385698081 hasPublicationYear "2023" @default.
• W4385698081 type Work @default.
• W4385698081 citedByCount "0" @default.
• W4385698081 crossrefType "journal-article" @default.
• W4385698081 hasAuthorship W4385698081A5012295709 @default.
• W4385698081 hasAuthorship W4385698081A5054467773 @default.
• W4385698081 hasAuthorship W4385698081A5090573083 @default.
• W4385698081 hasBestOaLocation W43856980811 @default.
• W4385698081 hasConcept C126322002 @default.
• W4385698081 hasConcept C142724271 @default.
• W4385698081 hasConcept C143998085 @default.
• W4385698081 hasConcept C146357865 @default.
• W4385698081 hasConcept C151730666 @default.
• W4385698081 hasConcept C194409129 @default.
• W4385698081 hasConcept C2778559949 @default.
• W4385698081 hasConcept C2779338263 @default.
• W4385698081 hasConcept C2780007613 @default.
• W4385698081 hasConcept C2780653079 @default.
• W4385698081 hasConcept C71924100 @default.
• W4385698081 hasConcept C86803240 @default.
• W4385698081 hasConceptScore W4385698081C126322002 @default.
• W4385698081 hasConceptScore W4385698081C142724271 @default.
• W4385698081 hasConceptScore W4385698081C143998085 @default.
• W4385698081 hasConceptScore W4385698081C146357865 @default.
• W4385698081 hasConceptScore W4385698081C151730666 @default.
• W4385698081 hasConceptScore W4385698081C194409129 @default.
• W4385698081 hasConceptScore W4385698081C2778559949 @default.
• W4385698081 hasConceptScore W4385698081C2779338263 @default.
• W4385698081 hasConceptScore W4385698081C2780007613 @default.
• W4385698081 hasConceptScore W4385698081C2780653079 @default.
• W4385698081 hasConceptScore W4385698081C71924100 @default.
• W4385698081 hasConceptScore W4385698081C86803240 @default.
• W4385698081 hasIssue "S3" @default.
• W4385698081 hasLocation W43856980811 @default.
• W4385698081 hasLocation W43856980812 @default.
• W4385698081 hasOpenAccess W4385698081 @default.
• W4385698081 hasPrimaryLocation W43856980811 @default.
• W4385698081 hasRelatedWork W1598567296 @default.
• W4385698081 hasRelatedWork W1996279342 @default.
• W4385698081 hasRelatedWork W2141506168 @default.
• W4385698081 hasRelatedWork W2171422777 @default.
• W4385698081 hasRelatedWork W2348836856 @default.
• W4385698081 hasRelatedWork W2369117338 @default.
• W4385698081 hasRelatedWork W2416406993 @default.
• W4385698081 hasRelatedWork W2418591842 @default.
• W4385698081 hasRelatedWork W3031860663 @default.
• W4385698081 hasRelatedWork W74504067 @default.
• W4385698081 hasVolume "7" @default.
• W4385698081 isParatext "false" @default.
• W4385698081 isRetracted "false" @default.
• W4385698081 workType "article" @default.